T. Dort

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

J. Lechner-Scott, M. Trojano, F. Grand'Maison, 2021, PharmacoEconomics.

The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden

M. Connolly, A. Kavaliunas, N. Kotsopoulos, 2020, Journal of medical economics.

Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study

A. Madan, M. Kosinski, M. Hayney, 2019, Health and Quality of Life Outcomes.

Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden

N. Armstrong, J. Lycke, T. Lundqvist, 2021, Journal of medical economics.

Does Investment Spur Growth Everywhere? Not Where Institutions are Weak

Khalid Sekkat, Pierre-Guillaume Méon, T. Dort, 2014 .